{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:39:08Z","timestamp":1793219948871,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T00:00:00Z","timestamp":1423526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T00:00:00Z","timestamp":1423526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1038\/pcan.2015.2","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T11:42:19Z","timestamp":1423568539000},"page":"144-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Prospective evaluation of low-dose ketoconazole plus hydrocortisone in docetaxel pre-treated castration-resistant prostate cancer patients"],"prefix":"10.1038","volume":"18","author":[{"given":"E N","family":"Lo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L A","family":"Beckett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C-X","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"P N","family":"Lara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"BFpcan20152_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1006\/taap.2000.9062","volume":"169","author":"RJ Chen","year":"2000","unstructured":"Chen RJ, Lee WS, Liang YC, Lin JK, Wang YJ, Lin CH et al. Ketoconazole induces G0\/G1 arrest in human colorectal and hepatocellular carcinoma cell lines. Toxicol Appl Pharmacol 2000; 169: 132\u2013141.","journal-title":"Toxicol Appl Pharmacol"},{"key":"BFpcan20152_CR2","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0022-5347(17)40639-2","volume":"141","author":"T Eichenberger","year":"1989","unstructured":"Eichenberger T, Trachtenberg J, Toor P, Keating A . Ketoconazole: a possible direct cytotoxic effect on prostate carcinoma cells. J Urol 1989; 141: 190\u2013191.","journal-title":"J Urol"},{"key":"BFpcan20152_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/BF00264198","volume":"21","author":"CF Rochlitz","year":"1988","unstructured":"Rochlitz CF, Damon LE, Russi MB, Geddes A, Cadman EC . Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 1988; 21: 319\u2013322.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFpcan20152_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/pros.21447","volume":"72","author":"D Keizman","year":"2012","unstructured":"Keizman D, Huang P, Carducci MA, Eisenberger MA . Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate 2012; 72: 461\u2013467.","journal-title":"Prostate"},{"key":"BFpcan20152_CR5","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0022-5347(05)64675-7","volume":"168","author":"KA Harris","year":"2002","unstructured":"Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ . Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 2002; 168: 542\u2013545.","journal-title":"J Urol"},{"key":"BFpcan20152_CR6","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.22085","volume":"107","author":"M Nakabayashi","year":"2006","unstructured":"Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK et al. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 2006; 107: 975\u2013981.","journal-title":"Cancer"},{"key":"BFpcan20152_CR7","doi-asserted-by":"crossref","first-page":"811","DOI":"10.47102\/annals-acadmedsg.V36N10p811","volume":"36","author":"LS Ngo","year":"2007","unstructured":"Ngo LS, Yeo A, Wong AS, Tay MH . Efficacy of low-dose ketoconazole in hormone refractory prostate cancer patients at the National Cancer Centre and The Cancer Institute, Singapore. Ann Acad Med Singapore 2007; 36: 811\u2013814.","journal-title":"Ann Acad Med Singapore"},{"key":"BFpcan20152_CR8","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513\u20131520.","journal-title":"N Engl J Med"},{"key":"BFpcan20152_CR9","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502\u20131512.","journal-title":"N Engl J Med"},{"key":"BFpcan20152_CR10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995\u20132005.","journal-title":"N Engl J Med"},{"key":"BFpcan20152_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368: 138\u2013148.","journal-title":"N Engl J Med"},{"key":"BFpcan20152_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187\u20131197.","journal-title":"N Engl J Med"},{"key":"BFpcan20152_CR13","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/annonc\/mdp199","volume":"20","author":"MD Galsky","year":"2009","unstructured":"Galsky MD, Simon K, Sonpavde G, Hutson TE, Fleming M, Kondagunta GV et al. Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol 2009; 20: 965\u2013966.","journal-title":"Ann Oncol"},{"key":"BFpcan20152_CR14","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1111\/j.1464-410X.2009.08971.x","volume":"105","author":"M Nakabayashi","year":"2010","unstructured":"Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW et al. Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer. BJU Int 2010; 105: 1392\u20131396.","journal-title":"BJU Int"},{"key":"BFpcan20152_CR15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1200\/JCO.2004.06.037","volume":"22","author":"EJ Small","year":"2004","unstructured":"Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22: 1025\u20131033.","journal-title":"J Clin Oncol"},{"key":"BFpcan20152_CR16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/pros.22765","volume":"74","author":"A Peer","year":"2014","unstructured":"Peer A, Gottfried M, Sinibaldi V, Carducci MA, Eisenberger MA, Sella A et al. Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel. Prostate 2014; 74: 433\u2013440.","journal-title":"Prostate"},{"key":"BFpcan20152_CR17","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.1200\/JCO.2007.11.4769","volume":"25","author":"AJ Armstrong","year":"2007","unstructured":"Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965\u20133970.","journal-title":"J Clin Oncol"},{"key":"BFpcan20152_CR18","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","volume":"27","author":"M Hussain","year":"2009","unstructured":"Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009; 27: 2450\u20132456.","journal-title":"J Clin Oncol"},{"key":"BFpcan20152_CR19","first-page":"S8","volume":"8","author":"A Kapoor","year":"2014","unstructured":"Kapoor A . What's new in prostate cancer research? Highlights of GU-ASCO 2014. Can Urol Assoc J 2014; 8: S8\u2013S12.","journal-title":"Can Urol Assoc J"},{"key":"BFpcan20152_CR20","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski J, Pezaro C, Bianchini D, Zivi A, Sandhu S, Thompson E et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23: 2943\u20132947.","journal-title":"Ann Oncol"},{"key":"BFpcan20152_CR21","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/annonc\/mdt136","volume":"24","author":"Y Loriot","year":"2013","unstructured":"Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24: 1807\u20131812.","journal-title":"Ann Oncol"},{"key":"BFpcan20152_CR22","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1002\/cncr.28285","volume":"119","author":"R Aggarwal","year":"2013","unstructured":"Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F et al. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer 2013; 119: 3636\u20133643.","journal-title":"Cancer"},{"key":"BFpcan20152_CR23","doi-asserted-by":"publisher","first-page":"e64275","DOI":"10.1371\/journal.pone.0064275","volume":"8","author":"L Zhong","year":"2013","unstructured":"Zhong L, Pon V, Srinivas S, Nguyen N, Frear M, Kwon S et al. Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis. PLoS One 2013; 8: e64275.","journal-title":"PLoS One"},{"key":"BFpcan20152_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1200\/JCO.2000.18.7.1440","volume":"18","author":"EJ Small","year":"2000","unstructured":"Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB et al. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000; 18: 1440\u20131450.","journal-title":"J Clin Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan20152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan20152","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan20152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T22:13:23Z","timestamp":1691187203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan20152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["BFpcan20152"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2015.2","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,10]]},"assertion":[{"value":"9 September 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}